Treatment for Glioma: Retrospect and Prospect

Dear Colleagues,

Gliomas are the most common malignant primary brain tumor in adults. Generally, gliomas are divided into circumscribed and diffuse types, with the former being benign and curable after complete surgical resection and almost exclusively affecting children, and the latter being more malignant and unable to be cured following surgical resection alone. Despite growing knowledge of the molecular changes responsible for tumor development, gliomas remain neoplasms with unmet medical needs. Until very recently, the gold standard treatment for gliomas was surgical resection followed by radiotherapy plus temozolomide, according to the STUPP protocol. It is noteworthy that molecular alterations could represent important prognostic factors and specific targets for precision medicine trials in primary and recurrent gliomas. In the last few years, many translational and clinical studies have been performed, and new treatments with targeted therapy, such as precision medicine, immunotherapy, and their combination, are ongoing.

This Special Issue will cover all aspects of primary and recurrent gliomas, including original research on advanced imaging, molecular characteristics, current and experimental treatment options, supportive care, neurocognitive functions, and quality of life. Expert opinions, systematic reviews, and meta-analyses are also welcome.

Dr. Andrea Landi
Dr. Valentina Baro
Prof. Dr. Giuseppe Lombardi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.